Return to study ST001467 main page
MB Sample ID: SA124416
| Local Sample ID: | BST200_3m |
| Subject ID: | SU001541 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO001536 |
| Collection Summary: | Mice were randomized into five groups (n = 10 each): untreated, non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of phosphate-buffered saline were subcutaneously implanted in the right flank of 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was assigned and drug administration started for 5-FU and BST204 groups. BST204 (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our study was determined according to IACUC guidelines, which recommend euthanasia with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our study period was limited to day 11. At this point, the change in tumor volumes was up to 810%, and significant cachexia was observed. |
| Sample Type: | Blood (plasma) |
| Collection Location: | muscle |
| Storage Conditions: | -20℃ |
